Notably, compared to the placebo group, immunohistochemical analysis showed that the administration of CW-MSC CM decreased Ki-67 and increased cleaved caspase 3 in tumor-invaded bone sections (Figure 3—figure supplement 3). The gene discussed is CASP3; the disease is neoplasm.